1. A pharmaceutical composition comprising an active substance selected from nicotinic acid, nicotinamide, tryptophan, a compound that is converted in the animal or human body to nicotinic acid, nicotinamide or tryptophan, nicotinamide adenine dinucleotide (NAD), nicotinamide adenine dinucleotide phosphate (NADP biosynthesis, or NADP, tryptophan dipeptide, or combinations thereof for beneficial effects on the intestinal microbiota, wherein said pharmaceutical composition releases an active substance for Local effects in the terminal ileum, colon or obeih.2. A pharmaceutical composition containing an active substance selected from nicotinic acid, nicotinamide, tryptophan or a combination thereof for a positive effect on the intestinal microbiota, where the pharmaceutical composition releases the active substance for local action in the terminal ileum, colon or both. 3. The pharmaceutical composition according to claim 1 or 2 for oral administration with a delayed release of the active ingredients for specific local effectiveness in the terminal ileum and / or colon. The pharmaceutical composition according to claim 3, prepared for oral administration, with a delayed release of the active ingredients for specific local effectiveness in the terminal ileum and / or colon. The pharmaceutical composition according to claim 1 or 2, prepared for oral administration, with controlled release of the active ingredients for specific local efficacy in terminal1. Фармацевтическая композиция, содержащая активное вещество, выбранное из никотиновой кислоты, никотинамида, триптофана, соединения, которое превращается в организме животного или человека в никотиновую кислоту, никотинамид или триптофан, никотинамидадениндинуклеотида (NAD), никотинамидадениндинуклеотидфосфата (NADP), промежуточного соединения в биосинтезе NAD или NADP, дипептида триптофана или их комбинации для положительного воздействия на кишечную микробиоту, где указанная фармацевтическая композиция высвобождает активно
